Maravai LifeSciences (NASDAQ:MRVI) Trading 5.2% Higher – Should You Buy?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price rose 5.2% during trading on Tuesday . The company traded as high as $5.79 and last traded at $5.71. Approximately 257,072 shares were traded during trading, a decline of 88% from the average daily volume of 2,233,504 shares. The stock had previously closed at $5.43.

Analyst Upgrades and Downgrades

MRVI has been the topic of a number of analyst reports. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. The Goldman Sachs Group downgraded Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Wolfe Research assumed coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Wells Fargo & Company started coverage on Maravai LifeSciences in a report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.03.

Maravai LifeSciences Stock Performance

The stock has a 50 day moving average price of $6.60 and a two-hundred day moving average price of $7.81. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -3.52 and a beta of -0.08.

Insider Buying and Selling at Maravai LifeSciences

In other news, insider Carl Hull acquired 175,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the transaction, the insider now owns 175,000 shares of the company’s stock, valued at approximately $987,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently made changes to their positions in MRVI. Point72 Asia Singapore Pte. Ltd. bought a new stake in Maravai LifeSciences during the 2nd quarter worth about $32,000. Blue Trust Inc. acquired a new stake in shares of Maravai LifeSciences during the 2nd quarter worth approximately $44,000. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $47,000. Custom Index Systems LLC bought a new stake in shares of Maravai LifeSciences during the third quarter worth approximately $97,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Maravai LifeSciences in the third quarter valued at approximately $105,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.